Literature DB >> 6987022

Spironolactone and amiloride in hypertensive patients with and without aldosterone excess.

W H Hoefnagels, J I Drayer, A G Smals, P W Kloppenborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6987022     DOI： 10.1038/clpt.1980.42

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

1.  ENaC inhibition stimulates HCl secretion in the mouse cortical collecting duct. I. Stilbene-sensitive Cl- secretion.

Authors:  Masayoshi Nanami; Yoskaly Lazo-Fernandez; Vladimir Pech; Jill W Verlander; Diana Agazatian; Alan M Weinstein; Hui-Fang Bao; Douglas C Eaton; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-29

Review 2.  [Modern pharmacological aspects of hyperaldosteronism therapy].

Authors:  M Quinkler; M Reincke
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

3.  ENaC inhibition stimulates Cl- secretion in the mouse cortical collecting duct through an NKCC1-dependent mechanism.

Authors:  Vladimir Pech; Monika Thumova; Young Hee Kim; Diana Agazatian; Edith Hummler; Bernard C Rossier; Alan M Weinstein; Masayoshi Nanami; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-11

Review 4.  Does kidney disease cause hypertension?

Authors:  Aldo J Peixoto; Marcelo Orias; Gary V Desir
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

5.  Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.